Climb Bio, Inc. CLYM
10.06 USD -0.30 (-2.90%)
As ofNov 16, 2026, 1:08 PM EST
10.04 Day range 10.57
1.64 52-week range 18.33
- YTD
- +151.50%
- 1 year
- +429.47%
News
benzinga.com Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27 Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $25 to $27.
benzinga.com Climb Bio Q3 EPS $(0.18) Beats $(0.20) Estimate Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 5.26 percent increase over losses of $(0.19) per…
benzinga.com Climb Bio To Present New Clinical Data For Budoprutug In Immune Thrombocytopenia At 68th ASH Annual Meeting And Exposition Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for…
benzinga.com Reported Saturday, Climb Bio Reports Initial PrisMN Phase 2 Data Showing 200 mg Budoprutug Delivered 70% Mean PLA2R Antibody Reduction, Immunologic Remission In 5 Of 13 Patients At Week 12 In pMN Low dose (200 mg) budoprutug demonstrated B-cell depletion, PLA2R Ab reduction, and immunologic remission at 12 weeks, consistent with Phase 1b data; additional data from the PrisMN Phase 2 study…
benzinga.com Climb Bio And Mabworks Report Phase 1 Data Supporting Quarterly CLYM116/MIL116 Dosing For IgA Nephropathy; Phase 3 Trial Expected In 2027 >90% free APRIL suppression sustained through 12 weeks, supporting Q12W dosing interval~70% reduction in Gd-IgA1 at 12 weeks~33-day half-lifeNAVIGATE-2 Phase 2 trial enrolling, with initial data…
benzinga.com Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28 Deutsche Bank analyst David Hoang initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating and announces Price Target of $28.
